All News
2021 Rheumatology Year in Review
Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read Article
New Onset Rheumatic Disorders with COVID-19 Infection
The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.
Read Article
Best of 2021: Jack of All Subspecialties
It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen journal articles, news reports and questions + cases.
Read Article
Best of 2021: High Risk Cancer Profiling with Inflammatory Myositis
A recent metanalysis of studies suggest you may be able to use certain clinical factors to stratify cancer risk in patients with idiopathic inflammatory myopathies (IIMs).
https://t.co/v4F3jmfnNK https://t.co/1lflsgMZtE
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis
The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced.
https://t.co/NczbrBXBl7 https://t.co/l93OM86qaX
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Fiorentino on cancer risk stratification and screening in myositis. Come chat at noon in the Myositis Community Hub to learn more!
#ACR21 #ACRAmbassador https://t.co/I0iQuPAuOl
Veena Katikineni VeenaRheumMD ( View Tweet)
Thanks Dr David Fiorentino for his talk on CA and myositis!
⬆️risk:
- DM
- >45-50yo
- males
- TIF1-gamma Ab (4.7RR of CA)
- NXP2
- low CK
- dysphagia
⬇️ risk:
- synthetase Ab
- raynaud
- ILD
- inflamm arth
🚨TIF1-gamma🚨
- ovarian CA (older, IgG2)
#ACR21 #ACRAmbassador
Vaneet K Sandhu, MD (she/her/hers) vksandhumd ( View Tweet)
I remember, not that long ago, inclusion body myositis evoked resignation, for pts & clinicians. A bizarre condition where standard of care was counselling/mitigation
Now there hope might be on the horizon
Exciting to see the science & a feasible target
#ACR21 ABSTL07 @RheumNow https://t.co/CYiAXIEA0Q
David Liew drdavidliew ( View Tweet)
Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
Richard Conway RichardPAConway ( View Tweet)
Knowledge Bowl at #ACR21
⭐️Approximately half of patients with IIM who develop pneumomediastinum have this subtype of dermatomyositis.
➡️Amyopathic (MDA5) dermatomyositis
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Bass on the ICI M triad: Myositis, Myocarditis, Myasthenia--> Strongly a/w morbidity & mortality
~0.4% frequency, mortality 22% when myositis alone
~Overlap (+ myasthenia or myocarditis) more common w/ combination ICI, mortality 42%
#ACR21 #ACRAmbassador https://t.co/g50tzAYhlS
Veena Katikineni VeenaRheumMD ( View Tweet)
If obvious dermatomyositis, you don’t need EMG for dx but may use for severity of involvement or if failing Rx or r/o steroid myopathy. For ?polymyositis ALWAYS do bx and often do EMG as broad differential #ACR21 @RheumNow https://t.co/L1xu3OuRYJ
Janet Pope Janetbirdope ( View Tweet)
@KatGilekMD @RichardPAConway @RheumNow @drhectorchinoy EMG/NCS can help uncover various neurological disorders including muscle dystrophies. Obviously it depends on center and expertise. Both MRI and EMG are useful and have different complementary utilities in Myositis. Many centers are not able to perform or interpret MRI reliably.
Rohit Aggarwal docrota ( View Tweet)
@NU_Rheum_MSK_US @RichardPAConway @drhectorchinoy @RheumNow Muscle ultrasound can be very useful but it is not ready for prime time currently to be used to do muscle biopsies. Perhaps in few years once we know how to target the muscle for biopsy.
Rohit Aggarwal docrota ( View Tweet)
Clinical (Peds Rheum) Pearl at #ACR21 by Dr. John Stone:
⭐️Dilated capillaries at the eyelid margin is the last cutaneous sign to resolve in inflammatory myositis!
⭐️Do not stop treatment until this sign is gone!
#ACRBest @RheumNow https://t.co/5H3Q9mTN9x
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR21 #Abstr0690 Great work by @didemsayginmd et al. 2016 ACR-EULAR Myositis Response Criteria concurred with patient-reported outcomes (muscle disease activity, strength, pain, fatigue, physical function, quality of life and physical activity) @RheumNow https://t.co/IV3mAXKhbt https://t.co/GWC6IDcJSm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Retrospective study of FAERS database: 186 irAE w/rheum manifestation
👉4.7% of all AEs
👉Arthritis, myositis, Sjogren, sarcoidosis were frequent
👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp
TheDaoIndex KDAO2011 ( View Tweet)
KL-6, Anti-Ku, anti-CENPB were assoc'd w/ #myositis &/or ILD in #lupus patients accdg to this study by Dr. T Cotton et al. This may help identify patients at risk for developing such.
@RheumNow #ACR21 abs0330 https://t.co/p0uxBOTLZm
sheila RHEUMarampa ( View Tweet)
In case you missed it…a popular read.
Clinical Associations with Myositis Antibodies
Read the full article on #RheumNow
https://t.co/tzPU1scc8x https://t.co/pmmtmIuz31
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Myositis Antibodies
Read the full post on #RheumNow
https://t.co/tzPU1scc8x https://t.co/F537tPAQTU
Links:
Dr. John Cush RheumNow ( View Tweet)
